Advances in Studies on Enzyme Inhibitors as Drugs. Volume 2: Miscellaneous Drugs

$275.00

Satya P. Gupta (Editor)
Professor Emeritus, National Institute of Technical Teacher’s Training and Research, Bhopal, India

Series: Pharmacology – Research, Safety Testing and Regulation
BISAC: MED071000

The book Advances in Studies on Enzyme Inhibitors as Drugs edited by eminent scientist Satya P. Gupta, covers the most recent development on design and discovery of the most useful drugs acting against several life threatening diseases such as cancer, viral infections and many others in two volumes. All of these drugs are based on inhibitions of various enzymes. Most human diseases are found to be associated with the overexpression of the enzymes. The book presents the structural aspects of various enzymes, their active sites, and the structural requirements of chemicals for strong interactions with enzymes. Volume One contains twelve chapters related to enzyme inhibitors acting as anticancer and antiviral drugs (each written by highly acclaimed authors), and Volume Two contains ten chapters on enzyme inhibitors acting against miscellaneous diseases written by equally competent authors. The book may be an asset for drug industries, research organizations, and individual researchers. (Imprint: Nova Biomedical)

Clear

Details

Table of Contents

Preface

Miscellaneous

Chapter 1. Protease Inhibitors as Potential Antimalarial Agents
Mange Ram Yadav, Mahesh A. Barmade and Prashant R. Murumkar (Faculty of Pharmacy, Kalabhavan Campus, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, India)

Chapter 2. Enzymatic Targets for Drug Discovery Against Alzheimer’s Disease
Mahua Basu, S. Balachandran, Nibha Mishra, and Arijit Basu (St. Xavier’s College 30, Mother Teresa Sarani, Kolkata, India, and others)

Chapter 3. Design and Development of Some Selective Enzyme Inhibitors for Parkinson’s and Alzheimer’s Diseases Based on Molecular Modeling and Dynamics Studies
Achintya Saha, Sagar S. Bhayye and Tabassum Hossain (Department of Chemical Technology, University of Calcutta, Kolkata, West Bengal, India)

Chapter 4. Pyruvate Dehydrogenase Kinases (PDHKs) and Their Inhibition: A Possible Line of Treatment for Diabetes, Heart Ischemia and Cancer
Rita Kakkar and Mamta Bhandari (Computational Chemistry Group, Department of Chemistry, University of Delhi, Delhi, India)

Chapter 5. Advances in Studies on COX/LOX Enzymes Inhibitors as Drugs
Pontiki Eleni and Hadjipavlou-Litina Dimitra (Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece)

Chapter 6. Design and Development of Matrix Metalloproteinase Inhibitors Containing Zinc-Binding Groups, without Zinc-Binding Groups, and Mechanism-Based
Nilanjan Adhikari, Sandip Kumar Baidyaa, Achintya Saha, Nahid Ali, and Tarun Jha (Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India, and others)

Chapter 7. Computational Study of D-Amino Acid Oxidase and Its Inhibitors
Kiattisak Lugsanangarm, Kanin Wichapong, Nadtanet Nunthaboot, Arthit Nueangaudom, Somsak Pianwanit, Fumio Tanaka, and Sirirat Kokpol (Program of Chemistry, Faculty of Science and Technology, Bansomdej Chaopraya Rajabhat University, Bangkok, Thailand, and others)

Chapter 8. Cytochrome P450 Inhibitors Used as Drugs
Dolly A. Parasrampuria (Clinical Pharmacology & Pharmacometrics, Janssen Research & Development, LLC, Titusville, New Jersey, United States of America)

Chapter 9. Quantum Chemical Insights into Metabolic Inhibition of Cytochrome P450 Enzymes: Piperine, Curcumin, and Metal Complexes of Curcumin: Promises and Bioavailability
Krishnan Balasubramanian (School of Molecular Sciences, Arizona State University, Tempe, Arizona, United States of America)

Chapter 10. Design and Development of Angiotensin-Converting Enzyme Inhibitors
Satish B. Bhise (KLK Consultants, Navkar Residency, Behind Bibvewadi Police Station, Bibvewadi, Pune, Maharashtra, India)

About the Editor

Index

Additional information

Binding

,